艾曲泊帕治疗需治疗的新诊断儿童免疫性血小板减少症:PINES随机临床试验
这项3期随机临床试验在北美儿童ITP联盟23个中心纳入118例需药物治疗但无严重出血的新诊断儿童免疫性血小板减少症患者,比较艾曲泊帕与标准治疗。艾曲泊帕组持续血小板应答率为65%,标准治疗组为35%,组间差异30%(95%CI 11%-49%;P=.002),两组不良事件数量和类型无组间差异。
要点
- 艾曲泊帕组持续血小板应答46/71例(65%),标准治疗组13/37例(35%),组间差异30%(95%CI 11%-49%;P=.002)。
- 持续血小板应答定义为第6至12周4次血小板计数中至少3次大于50×10⁹/L且未接受挽救治疗。
- 两组不良事件数量和类型无组间差异。
核心结论
- 在需药物治疗的新诊断儿童免疫性血小板减少症患者中,艾曲泊帕较标准治疗获得更高的持续血小板应答率。
- 艾曲泊帕可能是有非严重出血且需医疗干预的新诊断儿童免疫性血小板减少症患者的有效选择。
研究设计与样本
- 3期随机临床试验,于2019年5月7日至2024年1月25日在北美儿童ITP联盟23个中心纳入118例1至<18岁新诊断原发性免疫性血小板减少症患者。
- 纳入标准为血小板计数<30×10⁹/L、需药物治疗但无严重出血或无需快速提升血小板计数。
- 艾曲泊帕组78例按标准给药方案口服,标准治疗组40例由研究者选择糖皮质激素、静脉注射免疫球蛋白或抗D免疫球蛋白。
- 末次随访时间为2025年2月26日。
- 计划期中分析达到预设疗效阈值后终止入组。
主要发现
- 118例患儿中位年龄8岁(IQR 4-12岁),49%为男性,63%在观察或药物治疗后出现初始治疗失败。
- 艾曲泊帕组71例中46例(65%[95%CI 54%-76%])达到持续血小板应答,标准治疗组37例中13例(35%[95%CI 20%-51%])达到持续血小板应答。
- 组间差异为30%(95%CI 11%-49%;P=.002),跨过疗效监测边界。
- 两组不良事件数量和类型总体无组间差异。
关键数值与推荐
- 主要结局为持续血小板应答,定义为第6至12周4次血小板计数中至少3次大于50×10⁹/L且未接受挽救治疗。
- 次要结局包括出血评分、健康相关生活质量变化和严重不良事件。
临床怎么用
- 原文结论指出艾曲泊帕可能是有非严重出血且需医疗干预的新诊断儿童免疫性血小板减少症患者的有效选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Eltrombopag, a thrombopoietin receptor agonist, is approved by the US Food and Drug Administration for children with chronic immune thrombocytopenia. Efficacy of eltrombopag during the newly diagnosed phase of pediatric immune thrombocytopenia is unknown. OBJECTIVE: To determine if the proportion of patients with a platelet response is significantly greater in patients with newly diagnosed immune thrombocytopenia treated with eltrombopag than in those treated with standard therapy (first-line treatments). DESIGN, SETTING, AND PARTICIPANTS: This phase 3, randomized clinical trial enrolled patients (aged 1-<18 years) with newly diagnosed primary immune thrombocytopenia (platelet count <30 × 109/L who required pharmacological treatment but did not have severe bleeding or need a rapid increase in platelet count) from May 7, 2019, to January 25, 2024, at 23 centers participating in the Pediatric ITP Consortium of North America. Final follow-up occurred on February 26, 2025. INTERVENTIONS: Eltrombopag was administered orally based on a standard dosing schedule (n = 78) vs standard therapy (investigator choice of glucocorticoids, intravenous immunoglobulin, or anti-D immunoglobulin) (n = 40). MAIN OUTCOMES AND MEASURES: The primary outcome was a sustained platelet response defined as 3 or more of 4 platelet counts greater than 50 × 109/L during weeks 6 to 12 without rescue treatment. The secondary outcomes included bleeding scores, change in health-related quality of life, and serious adverse events. RESULTS: Of 118 pediatric patients (median age, 8 years [IQR, 4-12 years]; 49% were male), 63% experienced an initial treatment failure after observation or medical therapy. Enrollment ended after a planned interim analysis met a prespecified threshold for efficacy. Of 71 patients in the eltrombopag group, 46 (65% [95% CI, 54%-76%]) had a sustained platelet response compared with 13 of 37 patients (35% [95% CI, 20%-51%]) in the standard therapy group (between-group difference, 30% [95% CI, 11%-49%]; P = .002), which crossed the monitoring boundary for efficacy. Overall, there was no between-group difference in the number and type of adverse events. CONCLUSIONS AND RELEVANCE: In pediatric patients with newly diagnosed immune thrombocytopenia requiring pharmacological treatment, eltrombopag resulted in a higher rate of sustained platelet response compared with standard therapy. Eltrombopag may be an effective option for pediatric patients with newly diagnosed immune thrombocytopenia with nonsevere bleeding who warrant medical intervention. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03939637.
引用
- Shimano KA, Grimes AB, Kaicker S, et al. Eltrombopag for Newly Diagnosed Pediatric Immune Thrombocytopenia Requiring Treatment: The PINES Randomized Clinical Trial. JAMA. 2025. PMID: 41123939. doi:10.1001/jama.2025.18168
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。